Content about Catalyst

November 16, 2011

When its blockbuster cholesterol drug Lipitor loses patent protection this month, Pfizer is hoping that pharmacy benefit managers will not dispense a generic version of the drug to its customers, according to published reports.

NEW YORK — When its blockbuster cholesterol drug Lipitor loses patent protection this month, Pfizer is hoping that pharmacy benefit managers will not dispense a generic version of the drug to its customers, according to published reports.

Pharmacy benefit managers Medco and Catalyst have agreed to block generic versions of Lipitor from reaching their customers until the end of May 2012, according to Bloomberg. Additionally, the company reportedly is in talks with Express Scripts to have the PBM also block generic versions from reaching customers as well.